Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway

Journal of Virology

Volumn 90, Issue 5, 2016, Pages 2372-2387

  Pattabhi, Sowmya ^a   Wilkins, Courtney R ^a   Dong, Ran ^a   Knoll, Megan L ^a   Posakony, Jeffrey ^b   Kaiser, Shari ^b   Mire, Chad E ^c   Wang, Myra L ^b   Ireton, Renee C ^a   Geisbert, Thomas W ^c   Bedard, Kristin M ^b   Iadonato, Shawn P ^a,b   Loo, Yueh Ming ^a   Gale, Michael ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Kineta Inc   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CELL PROTEIN; INTERFERON REGULATORY FACTOR 3; KIN 1400; KIN 1407; KIN 1408; KIN 1409; KIN 1410; RIG I LIKE RECEPTOR; SMALL MOLECULE AGONIST; UNCLASSIFIED DRUG; VIRUS RNA; IMMUNOLOGIC FACTOR;

ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; DRUG STRUCTURE; EBOLAVIRUS; FLAVIVIRIDAE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOMODULATION; INFLUENZA A VIRUS; INNATE IMMUNITY; LASSA VIRUS; NIPAH VIRUS; NONHUMAN; PRIORITY JOURNAL; RNA VIRUS INFECTION; TRANSCRIPTION INITIATION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; WEST NILE VIRUS; ANIMAL; CELL LINE; DRUG EFFECTS; GENE EXPRESSION PROFILING; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHYSIOLOGY; RNA VIRUS; VIRUS CULTURE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; RNA VIRUSES; VIRAL LOAD; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84961144521     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02202-15     Document Type: Article

References (47)

1. Chancey C, Grinev A, Volkova E, Rios M. 2015. The global ecology and epidemiology of West Nile virus. Biomed Res Int 2015:376230. http://dx.doi.org/10.1155/2015/376230.
2. Fredericks AC, Fernandez-Sesma A. 2014. The burden of dengue and chikungunya worldwide: implications for the southern United States and California. Ann Glob Health 80:466-475. http://dx.doi.org/10.1016/j.aogh.2015.02.006.
3. World Health Organization. 2015. Impact of dengue. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/disease/dengue/impact/en/.
4. Ireton RC, Gale M, Jr. 2014. Pushing to a cure by harnessing innate immunity against hepatitis C virus. Antiviral Res 108:156-164. http://dx.doi.org/10.1016/j.antiviral.2014.05.012.
5. Hilgenfeldt EG, Schlachterman A, Firpi RJ. 2015. Hepatitis C: treatment of difficult to treat patients. World J Hepatol 7:1953-1963. http://dx.doi.org/10.4254/wjh.v7.i15.1953.
6. World Health Organization. 2015. Ebola situation report. World Health Organization, Geneva, Switzerland. http://apps.who.int/ebola/current-situation/ebola-situation-report-12-august-2015.
7. Debing Y, Jochmans D, Neyts J. 2013. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 3:217-224. http://dx.doi.org/10.1016/j.coviro.2013.03.001.
8. Kell AM, Gale M, Jr. 2015. RIG-I in RNA virus recognition. Virology 479-480:110-121. http://dx.doi.org/10.1016/j.virol.2015.02.017.
9. Rodriguez KR, Bruns AM, Horvath CM. 2014. MDA5 and LGP2: accomplices and antagonists of antiviral signal transduction. J Virol 88: 8194-8200. http://dx.doi.org/10.1128/JVI.00640-14.
10. Chow J, Franz KM, Kagan JC. 2015. PRRs are watching you: localization of innate sensing and signaling regulators. Virology 479-480:104-109. http://dx.doi.org/10.1016/j.virol.2015.02.051.
11. Mansur DS, Smith GL, Ferguson BJ. 2014. Intracellular sensing of viral DNA by the innate immune system. Microbes Infect 16:1002-1012. http://dx.doi.org/10.1016/j.micinf.2014.09.010.
12. Loo YM, Gale M, Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34:680-692. http://dx.doi.org/10.1016/j.immuni.2011.05.003.
13. Goulet ML, Olagnier D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, Janelle V, Arguello M, Paquet M, Ghneim K, Richards S, Smith A, Wilkinson P, Cameron M, Kalinke U, Qureshi S, Lamarre A, Haddad EK, Sekaly RP, Peri S, Balachandran S, Lin R, Hiscott J. 2013. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog 9:e1003298. http://dx.doi.org/10.1371/journal.ppat.1003298.
14. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, Jr. 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454:523-527. http://dx.doi.org/10.1038/nature07106.
15. Bedard KM, Wang ML, Proll SC, Loo YM, Katze MG, Gale M, Jr, Iadonato SP. 2012. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J Virol 86:7334-7344. http://dx.doi.org/10.1128/JVI.06867-11.
16. Keller BC, Fredericksen BL, Samuel MA, Mock RE, Mason PW, Diamond MS, Gale M, Jr. 2006. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 80:9424-9434. http://dx.doi.org/10.1128/JVI.00768-06.
17. Kato T, Date T, Murayama A, Morikawa K, Akazawa D, Wakita T. 2006. Cell culture and infection system for hepatitis C virus. Nat Protoc 1:2334-2339. http://dx.doi.org/10.1038/nprot.2006.395.
18. Liu HM, Loo YM, Horner SM, Zornetzer GA, Katze MG, Gale M, Jr. 2012. The mitochondrial targeting chaperone 14-3-3epsilon regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. Cell Host Microbe 11:528-537. http://dx.doi.org/10.1016/j.chom.2012.04.006.
19. Horner SM, Park HS, Gale M, Jr. 2012. Control of innate immune signaling and membrane targeting by the hepatitis C virus NS3/4A protease are governed by the NS3 helix alpha0. J Virol 86:3112-3120. http://dx.doi.org/10.1128/JVI.06727-11.
20. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675. http://dx.doi.org/10.1038/nmeth.2089.
21. Schnell G, Loo YM, Marcotrigiano J, Gale M, Jr. 2012. Uridine composition of the poly-U/UC tract ofHCVRNAdefines non-self recognition by RIG-I. PLoS Pathog 8:e1002839. http://dx.doi.org/10.1371/journal.ppat.1002839.
22. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80. http://dx.doi.org/10.1186/gb-2004-5-10-r80.
23. Smyth GK. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3.
24. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC, Lempicki RA. 2007. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol 8:R183. http://dx.doi.org/10.1186/gb-2007-8-9-r183.
25. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA. 2007. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35:W169-W175. http://dx.doi.org/10.1093/nar/gkm415.
26. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14:128. http://dx.doi.org/10.1186/1471-2105-14-128.
27. Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R, Winsor GL, Hancock RE, Brinkman FS, Lynn DJ. 2013. InnateDB: systems biology of innate immunity and beyond-recent updates and continuing curation. Nucleic Acids Res 41:D1228-D1233. http://dx.doi.org/10.1093/nar/gks1147.
28. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207-210. http://dx.doi.org/10.1093/nar/30.1.207.
29. Lin R, Mamane Y, Hiscott J. 1999. Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol Cell Biol 19:2465-2474. http://dx.doi.org/10.1128/MCB.19.4.2465.
30. Fensterl V, Sen GC. 2015. Interferon-induced Ifit proteins: their role in viral pathogenesis. J Virol 89:2462-2468. http://dx.doi.org/10.1128/JVI.02744-14.
31. Foy E, Li K, Wang C, Sumpter R, Jr, Ikeda M, Lemon SM, Gale M, Jr. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148. http://dx.doi.org/10.1126/science.1082604.
32. Hornung V, Hartmann R, Ablasser A, Hopfner KP. 2014. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat Rev Immunol 14:521-528. http://dx.doi.org/10.1038/nri3719.
33. MacMicking JD. 2012. Interferon-inducible effector mechanisms in cellautonomous immunity. Nat Rev Immunol 12:367-382. http://dx.doi.org/10.1038/nri3210.
34. Wang C, Pflugheber J, Sumpter R, Jr, Sodora DL, Hui D, Sen GC, Gale M, Jr. 2003. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77:3898-3912. http://dx.doi.org/10.1128/JVI.77.7.3898-3912.2003.
35. Diamond MS, Farzan M. 2013. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 13:46-57. http://dx.doi.org/10.1038/nri3344.
36. Haller O, Staeheli P, Schwemmle M, Kochs G. 2015. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 23:154-163. http://dx.doi.org/10.1016/j.tim.2014.12.003.
37. Verhelst J, Hulpiau P, Saelens X. 2013. Mx proteins: antiviral gatekeepers that restrain the uninvited. Microbiol Mol Biol Rev 77:551-566. http://dx.doi.org/10.1128/MMBR.00024-13.
38. Verhelst J, Parthoens E, Schepens B, Fiers W, Saelens X. 2012. Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly. J Virol 86:13445-13455. http://dx.doi.org/10.1128/JVI.01682-12.
39. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975-990. http://dx.doi.org/10.1038/nrd2422.
40. Mueller NH, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson TC, Padmanabhan R. 2008. Identification and biochemical characterization of small-molecule inhibitors of West Nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother 52: 3385-3393. http://dx.doi.org/10.1128/AAC.01508-07.
41. Wainberg MA, Zaharatos GJ, Brenner BG. 2011. Development of antiretroviral drug resistance. N Engl J Med 365:637-646. http://dx.doi.org/10.1056/NEJMra1004180.
42. Mesplede T, Wainberg MA. 2015. Resistance against integrase strand transfer inhibitors and relevance to HIV persistence. Viruses 7:3703-3718. http://dx.doi.org/10.3390/v7072790.
43. Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. 2014. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 28: 813-819. http://dx.doi.org/10.1097/QAD.0000000000000199.
44. Berger KL, Scherer J, Ranga M, Sha N, Stern JO, Quinson AM, Kukolj G. 2015. Baseline polymorphisms and emergence of drug resistance in the NS3/4A protease of hepatitis C virus genotype 1 following treatment with faldaprevir plus pegylated interferon alpha-2a/ribavirin in phase 2 and phase 3 studies. Antimicrob Agents Chemother 59:6017-6025. http://dx.doi.org/10.1128/AAC.00932-15.
45. Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Bocher WO, Datsenko Y, Steinmann G, Scherer J, Stern JO, Kukolj G. 2014. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother 58:698-705. http://dx.doi.org/10.1128/AAC.01976-13.
46. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. 2015. Resistance analysis of baseline and treatment-emergent variants in hepatitisCvirus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother 59:5445-5454. http://dx.doi.org/10.1128/AAC.00998-15.
47. Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. 2015. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother 59:6807-6815. http://dx.doi.org/10.1128/AAC.01229-15.